论文部分内容阅读
本文评论顺铂和卡铂之后的第三代铂抗癌药物的研究状况。报道其配合物的抗肿瘤活性、限量毒性、交叉耐药性和其中四种配合物的Ⅱ期临床结果。这些配合物的总体水平并不优于顺铂和卡铂。研究抗癌机理与顺铂和卡铂不同的新型铂配合物是增加该类药物的抗肿瘤活性和克服交叉耐药性的途径之一。
This article reviews the status of the third generation of platinum anticancer drugs after cisplatin and carboplatin. The antitumor activity, cytotoxicity, cross-resistance and the phase Ⅱ clinical results of four complexes were reported. The overall level of these complexes is not superior to cisplatin and carboplatin. Study of anti-cancer mechanism And cisplatin and carboplatin different new platinum complexes is to increase the anti-tumor activity of these drugs and overcome one of the ways of cross-resistance.